Immuneering (IMRX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

IMRX Immuneering

Watchlist

1.635
-0.335-17.01%

Close Dec 13 16:00 ET

1.630
-0.005-0.31%

Post 16:46 ET

50.77MMarket Cap-0.83P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Morgan Stanley Upgrades PTC, Cuts Immuneering, Amicus
Seeking Alpha14:42 ET
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Benzinga14:10 ET
Morgan Stanley Downgrades Immuneering to Underweight From Equalweight, Removes $4 Price Target, Sets Base Case Range of $1-$5
MT NewswiresDec 13 06:50 ET · Ratings
Morgan Stanley Downgrades Immuneering(IMRX.US) to Sell Rating
Moomoo NewsDec 12 20:32 ET · Ratings
Immuneering Granted FDA Fast Track Designation for IMM-1-104
TipRanksDec 12 08:05 ET
Express News | Immuneering Granted FDA Fast Track Designation for Imm-1-104 in Advanced Melanoma
ReutersDec 12 08:00 ET

Comments

Saint Jeremiah

1 hour ago

$Immuneering (IMRX.US)$ i glad i only bought 3 shares

Jaguar8

20 hours ago

🕗Watchlist FRIDAY December 13. NFA. Tired now so I’ll attach the watchlist for Thursday and Wednesday and check those which didn’t run yet. Remember it’s our lucky day tomorrow: Friday 13th

NOTE: Whenever a stock is up, make sure you check its dilution risk - cash on hand because most likely if they are cash-strapped, they will make offering. Scaling out is key. NEVER listen to those who say hold on because if you lose money, they wouldnt care AT ALL.
*************************************
REVERSE...

我要向钱看

Dec 12 07:08

EXPLODE

$Immuneering (IMRX.US)$ Hohoho....

Trytosaveabit

Dec 12 07:06

News

$Immuneering (IMRX.US)$ Reuters· 4 mins ago
Immuneering Granted FDA Fast Track Designation for Imm-1-104 in Advanced Melanoma

Jaguar8

Dec 12 07:00

NEWS

$Immuneering (IMRX.US)$
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
Thursday, 12th December at 8:00 am
- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors -
- IMM-1-104 was observed to be uniquely well tolerated in Phase 1 data shared at ESMO 2024, relative to MEK inhibitors currently used to treat melanoma -
- Melanoma patients actively enrolling in one of five arms in the co...

Heat List

Overall

No Data